DrugPatentWatch Database Preview
CALAN SR Drug Profile
see a sample report or, see our see our flat-rate plans
When do Calan Sr patents expire, and what generic alternatives are available?
The generic ingredient in CALAN SR is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
Summary for CALAN SR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 81 |
| Patent Applications: | 2,293 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | CALAN SR at DailyMed |
Pharmacology for CALAN SR
Medical Subject Heading (MeSH) Categories for CALAN SR
Synonyms for CALAN SR
| ( inverted question mark)-Verapamil hydrochloride |
| (??)-Verapamil hydrochloride |
| (?)-Verapamil hydrochloride |
| (+-)-5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile monohydrochloride |
| (+-)-Verapamil hydrochloride |
| (+/-)-VERAPAMIL HYDROCHLORIDE |
| (+/-)-Verapamil hydrochloride, >=99% (titration), powder |
| (+/-)-Verapamil hydrochloride, pharmaceutical secondary standard; traceable to USP and PhEur |
| (+/-)-Verapamil, Hydrochloride |
| (S)-(-)-Verapamil Hydrochloride |
| (y)-Verapamil hydrochloride |
| 152-11-4 |
| 152V114 |
| 2-(3,4-dimethoxyphenyl)-5-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]-2-isopropylpentanenitrile hydrochloride |
| 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-isopropyl-pentanenitrile hydrochloride |
| 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-propan-2-yl-pentanenitrile hydrochloride |
| 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile hydrochloride |
| 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile;hydrochloride |
| 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile hydrochloride |
| 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-isopropylpentanenitrile hydrochloride |
| 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]methylamino}-2-(methy lethyl)pentanenitrile, chloride |
| 23313-68-0 |
| 36622-29-4 |
| 38176-10-2 |
| 5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile hydrochloride |
| 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile monohydrochloride |
| 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile Hydrochloride |
| 54236-EP2305219A1 |
| 54236-EP2308562A2 |
| A816666 |
| AB0018370 |
| AC-16228 |
| AC-8483 |
| AC1L1Y4V |
| AC1Q3CE8 |
| Akilen |
| AKOS005267117 |
| AN-7969 |
| Anpec |
| API0024301 |
| Apo-Verap |
| ARONIS24174 |
| Arpamyl LP |
| AS-16018 |
| BBC/320 |
| BC210130 |
| Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, monohydrochloride |
| Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, monohydrochloride, (+-)- |
| Benzeneacetonitrile,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-, monohydrochloride |
| Berkatens |
| BG0353 |
| BIV1326 |
| C27H38N2O4.HCl |
| C27H39ClN2O4 |
| Calan (TN) |
| Calaptin |
| Calaptin 240 SR |
| Calcan hydrochloride |
| Cardiabeltin |
| Cardiagutt |
| Cardibeltin |
| Cardioprotect |
| CAS-152-11-4 |
| Caveril |
| CC-35585 |
| CCG-39491 |
| CHEMBL1280 |
| Civicor |
| Civicor Retard |
| Coraver |
| Cordilox SR |
| Corpamil |
| Covera |
| Covera-HS |
| Covera-hs (TN) |
| CS-1685 |
| D-365 hydrochloride |
| D00619 |
| Dignover |
| Dilacoran HTA |
| DOQPXTMNIUCOSY-UHFFFAOYSA-N |
| DSSTox_CID_14095 |
| DSSTox_GSID_34095 |
| DSSTox_RID_79114 |
| DTXSID2034095 |
| Durasoptin |
| EINECS 205-800-5 |
| Elthon |
| EN300-124002 |
| EU-0101237 |
| Flamon |
| FT-0603360 |
| FT-0655647 |
| Geangin |
| Harteze |
| Hexasoptin |
| Hexasoptin Retard |
| HMS1568M04 |
| HMS1922J16 |
| Hormitol |
| HSDB 3928 |
| HY-A0064 |
| I06-0615 |
| Ikacor |
| Ikapress |
| IN1425 |
| Inselon |
| Iproveratril hydrochloride |
| Isoptin Retard |
| Isoptin SR |
| Isoptino |
| Isotopin hydrochloride |
| Izoptin |
| Jenapamil |
| K-4825 |
| Lekoptin |
| Lodixal |
| LP01237 |
| LS-161199 |
| LU 20175 |
| Magotiron |
| Manidon |
| Manidon Retard |
| MFCD00055208 |
| MLS000069485 |
| MLS001055442 |
| MLS002222213 |
| MolPort-002-915-466 |
| NCGC00024710-03 |
| NCGC00094479-01 |
| NCGC00094479-02 |
| NCGC00094479-03 |
| NCGC00094479-04 |
| NCGC00094479-05 |
| NCGC00258732-01 |
| NCGC00261922-01 |
| Novapamyl LP |
| Novo-Veramil |
| NSC 135784 |
| NSC 272366 |
| NSC-272366 |
| NSC-657799 |
| NSC-759589 |
| NSC272366 |
| NSC657799 |
| NSC759589 |
| Nu-Verap |
| Opera_ID_1210 |
| OR075078 |
| OR245357 |
| Ormil |
| Pharmakon1600-02300307 |
| Praecicor |
| Prestwick_440 |
| Q-201923 |
| Quasar |
| R(+)-VERAPAMIL |
| R853 |
| Rapam |
| Robatelan |
| s4202 |
| SC-18887 |
| SCHEMBL33296 |
| SMR000059109 |
| SPECTRUM2300307 |
| ST066908 |
| ST24050346 |
| Tox21_201180 |
| Tox21_501237 |
| Univex |
| V 4629 |
| Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-, monohydrochloride |
| Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-,monohydrochloride |
| Vasolan (TN) |
| Vasomil |
| Vasopten |
| Vera-Sanorania |
| VERA? HYDROCHLORIDE |
| Verabeta |
| Veracaps SR |
| Veracor |
| Verahexal |
| Veraloc |
| Veramex |
| Veramil |
| Verapamil (hydrochloride) |
| Verapamil Acis |
| Verapamil AL |
| Verapamil Atid |
| Verapamil Basics |
| Verapamil chloridrate |
| Verapamil Ebewe |
| Verapamil HCl |
| Verapamil Henning |
| Verapamil hydrochloride |
| Verapamil Hydrochloride (Isoptin, Iproveratril, Calan) |
| Verapamil hydrochloride (JP17/USP) |
| Verapamil hydrochloride [USAN:JAN] |
| Verapamil hydrochloride [USAN:USP:JAN] |
| Verapamil Hydrochloride 1.0 mg/ml in Methanol (as free base) |
| Verapamil hydrochloride, European Pharmacopoeia (EP) Reference Standard |
| Verapamil hydrochloride, United States Pharmacopeia (USP) Reference Standard |
| Verapamil Injection |
| Verapamil MSD |
| Verapamil NM |
| Verapamil NM Pharma |
| Verapamil Nordic |
| Verapamil PB |
| Verapamil Riker |
| Verapamil SR |
| Verapamil Verla |
| Verapamil-AbZ |
| VERAPAMILHYDROCHLORIDE |
| Verapamyl hydrochloride |
| Verapin |
| Verapress 240 SR |
| Verasal |
| Verasifar |
| Veratensin |
| Verdilac |
| Verelan (TN) |
| Verelan SR |
| Veroptinstada |
| Verpamil |
| Vetrimil |
| Vortac |
| Z2210978706 |
| ZX-AFC000544 |
| ZX-AS004533 |
US Patents and Regulatory Information for CALAN SR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | CALAN SR | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019152-003 | Mar 6, 1991 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Pfizer | CALAN SR | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019152-002 | Dec 15, 1989 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Pfizer | CALAN SR | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019152-001 | Dec 16, 1986 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
see a sample report or, see our see our flat-rate plans
